Five decades of Fontan palliation: What have we learned? What should we expect?

被引:3
|
作者
Hassan, Adil [1 ]
Chegondi, Madhuradhar [2 ]
Porayette, Prashob [3 ]
机构
[1] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA
[2] Univ Iowa, Stead Family Childrens Hosp, Div Pediat Crit Care Med, Iowa City, IA 52242 USA
[3] Univ Iowa, Stead Family Childrens Hosp, Div Pediat Cardiol, Iowa City, IA 52242 USA
关键词
Single-ventricle physiology; Fontan; congenital heart disease; neurodevelopmental outcomes; adult congenital heart disease; arrhythmias; cyanosis; heart failure; cardiac transplantation; Fontan-associated liver disease; CONGENITAL HEART-DISEASE; PROTEIN-LOSING ENTEROPATHY; SINGLE VENTRICLE; CONSENSUS DOCUMENT; CLINICAL-OUTCOMES; AMERICAN-SOCIETY; VENOUS-PRESSURE; ARTERIAL DUCT; LONG-TERM; ADULTS;
D O I
10.1177/03000605231209156
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The Fontan procedure is the final palliative surgery in a series of staged surgeries to reroute the systemic venous blood flow directly to the lungs, with the ventricle(s) pumping oxygenated blood to the body. Advances in medical and surgical techniques have improved patients' overall survival after the Fontan procedure. However, Fontan-associated chronic comorbidities are common. In addition to chronic cardiac dysfunction and arrhythmias, complications involving other organs such as the liver, lungs, intestine, lymphatic system, brain, and blood frequently occur. This narrative review focuses on the immediate and late consequences in children, pregnant women, and other adults with Fontan circulation. In addition, we describe the technical advancements that might change the way single-ventricle patients are managed in future.
引用
收藏
页数:17
相关论文
共 50 条
  • [21] Mitral regurgitation and cardiac resynchronization therapy: how long and what should we expect?
    Cabrera-Bueno, Fernando
    Jose Molina-Mora, Maria
    Javier Alzueta-Rodriguez, Francisco
    EUROPACE, 2011, 13 (12): : 1801 - 1802
  • [22] What did we learn from the OPTIMAAL trial? What can we expect from VALIANT?
    Dickstein, K
    AMERICAN HEART JOURNAL, 2003, 145 (05) : 754 - 757
  • [23] Health Care for the Homeless: What We Have Learned in the Past 30 Years and What's Next
    Zlotnick, Cheryl
    Zerger, Suzanne
    Wolfe, Phyllis B.
    AMERICAN JOURNAL OF PUBLIC HEALTH, 2013, 103 : S199 - S205
  • [24] Personalizing antiplatelet therapies: What have we learned from recent trials?
    Landry, Sebastien
    Tanguay, Jean-Francois
    Lordkipanidze, Marie
    PLATELETS, 2018, 29 (02) : 131 - 139
  • [25] Calcium sensitizers: What have we learned over the last 25 years?
    Pollesello, P.
    Papp, Z.
    Papp, J. Gy.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 203 : 543 - 548
  • [26] What have we learned about cues to deception? A survey of expert opinions
    Luke, Timothy J.
    Giolla, Erik Mac
    Memon, Amina
    Landstrom, Sara
    Granhag, Paer Anders
    Kassin, Saul
    PSYCHOLOGY CRIME & LAW, 2023,
  • [27] Bioresorbable Vascular Scaffold for the Treatment of Coronary Bifurcations: What Have We Learned?
    Belardi, Jorge A.
    Albertal, Mariano
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2015, 86 (04) : 653 - 654
  • [28] What have we learned from 691 prenatal chromosomal microarrays for ventricular septal defects?
    Maya, Idit
    Singer, Amihood
    Yonath, Hagith
    Reches, Adi
    Rienstein, Shlomit
    Zeligson, Sharon
    Ben Shachar, Shay
    Sagi-Dain, Lena
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2020, 99 (06) : 757 - 764
  • [29] Should we prescribe physical activity in Fontan as a conventional therapy?
    Festa, Pierluigi
    Ali, Lamia Ait
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 255 : 59 - 60
  • [30] Cardiovascular effects of SGLT-2 inhibitors: What we have learned from cardiovascular outcome trials and what we still need to understand
    Cavallari, Ilaria
    Maddaloni, Ernesto
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2019, 35 (04)